



Nestlé investor
seminar 2022



Shaping a leader in Nutrition and Health

Greg Behar
CEO
Nestlé Health Science



Disclaimer

This presentation contains forward looking statements which reflect Management's current views and estimates. The forward looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those contained in the forward looking statements. Potential risks and uncertainties include such factors as general economic conditions, foreign exchange fluctuations, competitive product and pricing pressures and regulatory developments.

This presentation contains certain financial performance measures which are not defined by IFRS. Management believes that these non-IFRS measures provide additional useful information to assess the financial and operational performance of the Group. Such measures may not be comparable to similar measures presented by other companies and are explained and/or reconciled with our IFRS measures (Consolidated Financial Statements) in the Nestlé Group Alternative Performance Measures (APMs) document available on our Investor Website.

Key takeaways

Our leadership journey on nutrition and health is well underway



3 strategic imperatives

Boosting growth in the core

- Expanding geographically, enhancing category leadership and building customer partnerships

Differentiating through insights

- Understanding consumer/patient needs, leveraging R&D capabilities and innovation ecosystem

Unlocking growth via portfolio management

- Strengthening leadership through M&A and delivering on acquisition and synergy plans

Driving further value creation to 2025

Grow organically at a high single-digit rate

Reach underlying TOP margin of > 18%

Operating in segments with attractive long-term trends

**Aging
population**



**Focus on immunity,
health and
well-being**



**More people following
specialized diets
(e.g. keto, vegan, gluten-free)**



**Sustainability,
natural, organic,
non-GMO**



**Demand for
prevention and
self-care**



**Rise of chronic
diseases and allergy
prevalence**




**Shift to lower-cost
models of patient care
(e.g. at-home)**



Personalization



**Continuous access
to information
("Dr. Google")**



**Growing scientific
evidence for the impact
on nutrition and health**



Strong and focused portfolio


Market
size (CHF)

CAGR
2022-26


Market
share

Consumer Care

Vitamins, Minerals and Supplements (VMS)




~ 5%



Active Nutrition




~ 6%



Medical Nutrition



~ 5%




Strengthening our leadership through strong growth & margin development

Sales (CHF bn)

■ **Consumer Care**
(VMS & Active Nutrition)

■ **Medical Nutrition**



Organic growth

| | | |
|------------------|--|-------------------|
| Mid single-digit | | High single-digit |
|------------------|--|-------------------|

Underlying TOP margin

| | | |
|-----------|--|-------|
| Mid-teens | | > 18% |
|-----------|--|-------|

Placing *Palforzia* under strategic review

***Palforzia* has strong data**

- 67% desensitization rate for aged 4-17
- 74% for aged 1-4

Penetrating the U.S. market has been challenging

- Limited patient motivation (vs. continued peanut avoidance)
- Slow adoption by Health Care Professionals

Exploring strategic options

Expected to be completed in H1 2023

Continued commitment to allergy nutrition portfolio in Consumer Care and Medical Nutrition



Just completed clinical trials for ages 1 to < 4

Our strategy is focused on nutrition and metabolism



Focusing on our expertise in nutrition and metabolism


Playing selectively and with winning positions

| Consumer Care | | Medical Nutrition | | Where we do not play |
|----------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VMS | Everyday well-being | Disease specific medical nutrition | Malnutrition | <ul style="list-style-type: none"> Multi-level marketing / direct selling General over-the-counter/ personal care Diagnostics Broad-based pharma |
| | Mobility | | Surgery recovery | |
| | Gut health pro/prebiotics | | Cancer supportive care | |
| Metabolism | Weight management | Food allergy | | |
| | Pre-diabetes | | Pediatric food allergy | |
| | Diabetes | | | |
| Active Nutrition | Collagen | Nutrition related disorders | Gastrointestinal | |
| | Plant-based | | Metabolic disorders (especially Inborn errors of metabolism) | |
| | Healthy aging | | | |
| | Hydration | | | |
| | Sports nutrition (selectively) | Pediatric | Pediatric Medical Nutrition | |
|  Global market leader | |  Global leadership position (top 3) | | |

Powerful synergies between Consumer Care and Medical Nutrition




Boost market share in the U.S.



Recent growth has been solid over a high base of comparison

Total NHSc organic growth



Committed to doing business responsibly and sustainably



Managing our environmental footprint

Climate

Net zero by 2050

100% renewable electricity by 2025

Packaging

Close to 100% designed for recycling/reusable by 2025

Achieved zero waste to landfill in 2020*

Ingredients

Developing plant-based options and clean recipes

Responsible sourcing



Enhancing our social impact

Consumers/ Patients

Purpose centered around impacting people's health and wellbeing

B-Corp



nuun

Expected by 2023:




Orgain. VITAL PROTEINS

Diversity

50% of top positions and > 50% of management positions held by women

*Excluding factories from 2021/2022 acquisitions, which we aim to achieve by 2025


Drivers for continued growth and improved profitability

| 3 strategic imperatives | Key drivers |
|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  Boosting growth in the core | <ul style="list-style-type: none">• Extending category leadership• Expanding geographically• Building partnerships with customers |
|  Differentiating through insights | <ul style="list-style-type: none">• Understanding and addressing consumer & patient needs• Enhancing and accelerating our R&D capabilities• Building our health and wellness ecosystem |
|  Unlocking growth via portfolio management | <ul style="list-style-type: none">• Delivering on acquisition plans• Driving synergies and efficiencies• Active portfolio management |



Boosting
growth in the core

Omni-channel synergies between Consumer Care and Medical Nutrition




Channel split

Retail sales
including
department
stores / club

E-commerce

Hospitals &
homecare

Pharmacies
& drugstores






Boosting
growth in the core

Scaling our e-commerce capabilities

E-commerce as % of sales



#1 VMS brand on Amazon U.S. with Garden of Life, & 4 other brands in the top 8



#1 collagen brand in e-commerce



#1 Health Care Professional brand on Amazon



#1 D2C VMS brand in Brazil



#1 Allergy in China e-commerce, growing 2x faster than market



#3 in probiotics in China CBEC*, growing 3x faster than market



Industry leading D2C supplement brands


*CBEC – Cross Border E-commerce



Boosting
growth in the core

Fueling growth through geographic expansion

Where we are today



Our strategy

> 100 roll outs of specific brands
across 40 geographies



Supported by

Leading U.S.
positions

Existing NHSc
global presence

Local understanding
and know-how

Deep capabilities
in nutrition & health

Omni-channel
approach

Leverage the broader
Nestlé network



Differentiating
through insights

Key drivers of innovation

Speed of innovation



- **Innovation accelerator** driving fast launches and shop tests
- Vital Proteins gummies and collagen chocolate developed in 6 months

Digitalization



- Virtual support including coaching for **weight management** program, **weight loss** program and support program for **Crohn's disease**

R&D capabilities



- **Centre of Excellence** for liquids, powders, solid dose and gummies
- **Pilot and small batch** manufacturing

Disrupting with partnerships



48% of organic growth in 2022 from innovation/renovation (vs. 38% in 2018)

Incremental sales from products launched in the last 2 years



**Differentiating
through insights**

Shaping market trends through innovation

Metabolic health (Glucosmart)



Gastro-Intestinal (3 in one: pre + pro + postbiotics)



Healthy aging/ mitochondrial health



Food allergies (HMOs)



Sleep and immunity



Personalization & ecosystems





Unlocking growth via
portfolio management



Strengthening our portfolio through M&A

Orgain

PronoKal®

puravida 

the
BETTER
HEALTH
company

 THE
BOUNTIFUL
COMPANY

nuun

VITAL PROTEINS®

 Zenpep®
(pancrelipase)
Delayed-Release Capsules

 aimmune™
THERAPEUTICS

 persona™

 ATRIUM
INNOVATIONS

2018

2019

2020

2021

2022





Unlocking growth via
portfolio management

Model for M&A integration creates efficiencies and nurtures differentiation

Varied integration levels to
meet the unique needs of our
businesses



VITAL PROTEINS®

nuun

Orgain.

Dedicated brand capabilities

Marketing

Digital & e-commerce

Shared competencies to leverage NHSc breadth and scale

R&D

Sales

Operations &
supply chain

Back-office

Integrated technology backbone

Common leadership approach



Unlocking growth via
portfolio management



Significant cost synergy opportunities

